Concepedia

Author

Debu Tripathy

The University of Texas MD Anderson Cancer CenterORCID

Also Known As

Bora Lim, Brisbane Australia, D N TRIPATHY, D TRIPATHY, D Tripathy, D. TRIPATHY, D. Tripathy, Debasish Tripathy, Debu TRIPATHY, Debu Tripathy

1.2K

Publications

25.3K

Citations

68

H-Index

138

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterUniversity of California, San FranciscoUniversity of Southern CaliforniaThe University of Texas Southwestern Medical CenterDana-Farber Cancer Institute
DT

About

Debu Tripathy is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and breast cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

36

81

6.5K

2

Health Sciences

21

26

1.3K

3

Nursing

6

6

292

4

Public Health

5

5

179

5

Biostatistics

1

1

18

Debu Tripathy

×

210

Publications

21.2K

Citations

62

H-Index

YearCitations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh, Charles L. Vogel, Debu Tripathy,

Journal of Clinical Oncology

1999

2.8K

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer

Charles L. Vogel, Melody Cobleigh, Debu Tripathy,

Journal of Clinical Oncology

2002

1.8K

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

José Baselga, Debu Tripathy, John Mendelsohn,

Journal of Clinical Oncology

1996

1.4K

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Mark D. Pegram, A. Lipton, Daniel F. Hayes,

Journal of Clinical Oncology

1998

1.1K

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia,

New England Journal of Medicine

2019

987

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Debu Tripathy, Seock‐Ah Im, Marco Colleoni,

The Lancet Oncology

2018

973

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

Mark Jesus M. Magbanua, Lamorna Brown Swigart, H.-T. Wu,

Annals of Oncology

2020

418

Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

Adam Brufsky, Musa Mayer, Hope S. Rugo,

Clinical Cancer Research

2011

394

Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial

Christina M. Dieli‐Conwright, Kerry S. Courneya, Wendy Demark‐Wahnefried,

Journal of Clinical Oncology

2018

343

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

Jean‐Jacques Body, Ingo Diel, M. Lichinitzer,

British Journal of Cancer

2004

334

Page 1